{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:29:40Z","timestamp":1787725780464,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Combined immunotherapy of nivolumab plus ipilimumab for intermediate- and poor-risk metastatic clear cell renal cell carcinoma showed prolonged progression-free survival and high objective response rate in a randomized phase III clinical trial. However, the efficacy of this treatment for papillary renal cell carcinoma remains unclear. In the present study, we analysed the efficacy of nivolumab plus ipilimumab therapy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This is a retrospective study of 30 patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab as first-line therapy between December 2015 and May 2020. The objective response rate, progression-free survival and toxicity were compared between the two groups (clear cell renal cell carcinoma and papillary renal cell carcinoma).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 30 patients, 7 and 23 were diagnosed with papillary renal cell carcinoma and clear cell renal cell carcinoma, respectively. With a median follow-up of 7.2\u00a0months, the median progression-free survival was significantly shorter in papillary renal cell carcinoma than in clear cell renal cell carcinoma (2.4 vs. 28.1\u00a0months, P\u00a0=\u00a00.014). Of the seven patients with papillary renal cell carcinoma, one had partial response, one had stable disease and five had progressive disease, resulting in an objective response rate of 14.2%, which was lower compared to that of clear cell renal cell carcinoma (14.2 vs. 52.1%, P\u00a0=\u00a00.06). Discontinuation due to toxicity was not observed with papillary renal cell carcinoma, meanwhile 60.8% of patient with clear cell renal cell carcinoma discontinued treatment due to toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nivolumab plus ipilimumab had modest efficacy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma. Nivolumab plus ipilimumab remains an option for a limited number of patients with intermediate- or poor-risk papillary renal cell carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa229","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T07:08:38Z","timestamp":1604300918000},"page":"646-653","source":"Crossref","is-referenced-by-count":22,"title":["Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-9814","authenticated-orcid":false,"given":"Hidekazu","family":"Tachibana","sequence":"first","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-0943","authenticated-orcid":false,"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Izuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"2021040617300166800_ref1","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021040617300166800_ref2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2021040617300166800_ref3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2021040617300166800_ref4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2021040617300166800_ref5","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021040617300166800_ref6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021040617300166800_ref7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus Sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized Multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"2021040617300166800_ref8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French genitourinary group (GETUG)dagger","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"2021040617300166800_ref9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"2021040617300166800_ref10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.urology.2006.09.052","article-title":"Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification","volume":"69","author":"Pignot","year":"2007","journal-title":"Urology"},{"key":"2021040617300166800_ref11","volume-title":"Pathology and Genetics of Tumours of Urinary System and Male Genital Organs","author":"Eble","year":"2004"},{"key":"2021040617300166800_ref12","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021040617300166800_ref13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021040617300166800_ref14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","article-title":"Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis","volume":"67","author":"Vera-Badillo","year":"2015","journal-title":"Eur Urol"},{"key":"2021040617300166800_ref15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2015.07.008","article-title":"Anti-programmed cell death protein 1 (PD-1) antibody Nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with Sarcomatoid and Rhabdoid features","volume":"68","author":"Geynisman","year":"2015","journal-title":"Eur Urol"},{"key":"2021040617300166800_ref16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.juro.2017.04.067","article-title":"Outcomes of patients with renal cell carcinoma and Sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras","volume":"198","author":"Keskin","year":"2017","journal-title":"J Urol"},{"key":"2021040617300166800_ref17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clgc.2019.05.023","article-title":"Rapid deep responses with Nivolumab plus Ipilimumab in papillary renal cell carcinoma with Sarcomatoid dedifferentiation","volume":"17","author":"Schvartsman","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2021040617300166800_ref18","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.4049\/jimmunol.181.3.1835","article-title":"Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation","volume":"181","author":"Lages","year":"2008","journal-title":"J Immunol"},{"key":"2021040617300166800_ref19","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.4049\/jimmunol.171.5.2326","article-title":"The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors","volume":"171","author":"Miller","year":"2003","journal-title":"J Immunol"},{"key":"2021040617300166800_ref20","first-page":"1903","article-title":"Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: a case report","volume":"19","author":"Hori","year":"2020","journal-title":"Exp Ther Med"},{"key":"2021040617300166800_ref21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13691-018-0349-7","article-title":"Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases","volume":"8","author":"Matsushita","year":"2019","journal-title":"Int Cancer Conf J"},{"key":"2021040617300166800_ref22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11523-019-00660-6","article-title":"Predictive impact of peripheral blood markers and C-reactive protein in Nivolumab therapy for metastatic renal cell carcinoma","volume":"14","author":"Ishihara","year":"2019","journal-title":"Target Oncol"},{"key":"2021040617300166800_ref23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10147-019-01528-5","article-title":"C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2021040617300166800_ref24","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"2021040617300166800_ref25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with Sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2021040617300166800_ref26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021040617300166800_ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/4\/646\/36889125\/hyaa229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/4\/646\/36889125\/hyaa229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T16:15:32Z","timestamp":1617725732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/4\/646\/5992358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa229","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2020,11,20]]}}}